Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Bayer HealthCare To Evaluate Riociguat In New Indication - Quick Facts

Bayer HealthCare, a subsidiary of German conglomerate Bayer AG (BYR.L,BAYRY.PK,BAYZF.PK), announced the start of a randomized, double-blind, placebo-controlled Phase IIb study. The RISE-IIP study or Riociguat in Patients with Symptomatic Pulmonary HypErtension associated with Idiopathic Interstitial Pneumonias is designed to investigate the efficacy and safety of riociguat in patients with symptomatic pulmonary hypertension or PH associated with idiopathic interstitial pneumonia or IIP.

According to the company, the RISE-IIP trial will be carried out at more than 50 sites in 11 countries and will enroll approximately 120 patients. The study is designed as a 'signal-generating'study which may help to better understand the disease and the effect of riociguat on it. Based on the results, further steps will be decided.

Pulmonary hypertension or PH is a severe, progressive, life-changing and life-threatening disorder of the heart and lungs in which the blood pressure in the pulmonary arteries is above normal, and which can lead to heart failure and death.

Pulmonary Hypertension associated with Idiopathic Interstitial Pneumonia (PH-IIP) is a rare disease in which patients suffer both from pulmonary hypertension and idiopathic interstitial pneumonia or IIP.

Riociguat is a soluble guanylate cyclase or sGC stimulator, the first member of a novel class of compounds, discovered and developed by Bayer as an oral treatment to target a key molecular mechanism underlying PH. Riociguat is being investigated as a new and specific approach to treat different types of PH. sGC is an enzyme found in the cardiopulmonary system and the receptor for nitric oxide (NO). When NO binds to sGC, the enzyme enhances synthesis of the signaling molecule cyclic guanosine monophosphate or cGMP. cGMP plays an important role in regulating vascular tone, proliferation, fibrosis, and inflammation.

Register
To receive FREE breaking news email alerts for Bayer AG and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Stocks moved sharply lower over the course of the trading day on Wednesday, adding to the modest weakness seen in the two previous sessions. With the losses on the day, the major averages fell to their lowest closing levels in over a month. Democrats have climbed into the lead on a generic ballot, according to the results of a new CNN/ORC International poll, although the results may not be as positive for the party as they first appear. With spending on private and public construction both showing notable decreases, the Commerce Department released a report on Wednesday showing an unexpected drop in U.S. construction spending in the month of August.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.